How Payors May Improve Ophthalmic Specialty Drug Management and Control Costs
As demand for retinal therapies continues to rise—driven in part by a growing global patient population projected to reach nearly 288 million people with age-related macular degeneration by 20401—are facing increasing pressure around ophthalmic specialty drug management. High-cost biologics, an aging population, and the growing prevalence of chronic eye diseases are reshaping how care is delivered, and how it is paid for.
For many organizations, the challenge is no longer merely ensuring access to ophthalmic specialty therapies for providers and patients. It also means effectively managing ophthalmology specialty drug costs while maintaining quality outcomes.
The Growing Complexity of Ophthalmology Care
Ophthalmology has quickly become one of the most dynamic and costly specialty categories, with some retinal therapies, such as those for conditions like Wet Age-Related Macular Degeneration (Wet AMD), costing thousands of dollars per injection2.
This creates a unique set of challenges. Treatment volumes are high and therapies are costly, but care delivery depends on precise timing. Unfortunately, many managed care organizations lack clear visibility into how these drugs are sourced, billed and managed across provider networks.
Without a coordinated approach, ophthalmology drug access for managed care organizations can become fragmented, making it difficult to manage effectively and to predict costs.
Where Traditional Models Create Friction
The traditional buy-and-bill model has long been the standard in ophthalmology, but it was not originally designed for today’s level of complexity. While it allows providers to maintain control over drug inventory, it can also result in variability in sourcing, reimbursement, and cost transparency.
For payors, this may result in more limited visibility into how therapies are utilized and may create fewer opportunities to align them with pharmacy benefit coverage and reimbursement structures. Over time, this can contribute to a more reactive approach to ophthalmology drug management rather than a proactive one.
A More Coordinated Approach
To address these challenges, many organizations are adopting a more integrated model—one that more closely connects pharmacy, providers and payors through a coordinated approach to accessing, delivering and managing medications.
A well-designed ophthalmology specialty pharmacy program helps bring greater consistency to these processes. Instead of fragmented workflows, stakeholders operate within a shared framework that may improve visibility and reduce variability.
At its core, this type of coordinated ophthalmology drug supply model is designed to:
- Improve access to therapies
- Support provider workflows
- Support better cost management
The Impact on Managed Care Organizations
When implemented effectively, a coordinated managed care ophthalmology specialty pharmacy model may improve both cost management and patient care.
From a financial perspective, increased visibility into medication use may help organizations plan ahead and support more effective cost management. Aligning certain therapies under pharmacy coverage may also support greater control and predictability in how these medications are reimbursed.
On the operational side, a more coordinated approach makes processes clearer and easier to follow. Providers have a better understanding of how to order and receive medications, and health plans gain access to more consistent and reliable information. Over time, this supports better decision-making and more efficient operations.
There is also a direct impact on patient care. Programs that offer Wet AMD treatment support and diabetic macular edema specialty pharmacy services may feel confident that patients will receive their therapies on time and remain in treatment, both of which are critical for successful outcomes.
What’s Next for Ophthalmology Specialty Pharmacies
The ophthalmology landscape will only continue to grow in complexity as new therapies enter the market and patient demand increases. In this environment, fragmented approaches to drug management are becoming increasingly difficult to sustain.
Specialty pharmacy programs for retinal disease offer a more practical path forward by coordinating among pharmacies, providers and health plans. As a result, organizations may improve medication management, help ensure patients receive treatment on time and create a more consistent care experience.
The Future of Ophthalmology Specialty Drug Management
Managing ophthalmology specialty drugs requires more than access—it requires coordination. A thoughtful, integrated approach to specialty pharmacy ophthalmology services may help managed care organizations balance cost control with quality care, ensuring patients receive the therapies they need without unnecessary disruption.
Learn how California Specialty Pharmacy supports coordinated ophthalmology drug management for managed care organizations with our new service, RetinaCare Complete, here: https://csprx.com/ophthalmology.
References:
- Technavio, Age-Related Macular Degeneration Market Analysis, July 2025
https://www.technavio.com/report/age-related-macular-degeneration-market-industry-analysisHealthline, Financial Health Spotlight: Yes, Medicare Can Cover Wet AMD Treatments, Jan 2026
https://www.healthline.com/health/medicare-coverage-wet-amd-treatments
Legal Disclaimer:
The content provided in this article is based on industry experience and is for informational purposes only. It is not intended to serve as legal, regulatory, or reimbursement advice. While we make every effort to provide accurate and up-to-date information, the details shared here should not be considered a substitute for professional consultation or advice.
By accessing this content, you agree to hold harmless the author, publisher, and any associated parties from any claims, liabilities, or damages arising from the use or interpretation of this content.
©2026 California Specialty Pharmacy, LLC. All rights reserved.
